Arzu AKŞAHİN, Dilşen ÇOLAK, Berkant SÖNMEZ, Birgül AY2, Yasemin Özden ELDEMİR2, Mustafa ALTINBAŞ

Küçük hücreli akciğer kanserli hastalarda kesitsel çalışma: Trombositopeni sıklığı

Amaç: Bu çalışmada küçük hücreli akciğer kanseri vakalarımızın demografk ve diğer özelliklerinin yanında tanıanında kesitsel olarak trombositopeni sıklığını değerlendirmek istedik. Gereç ve Yöntem: Tek merkezli, retrospektif bir çalışmadır. Ocak 2008 ile Mayıs 2011 arasında Tıbbi Onkoloji üni-tesinde takip edilmiş olan KHAKli vakaları incelendik.Çalışmada hastaların tanı anında olan parametreleri değerlendirmeye alındı.Verilerin analizinde SPSS version.14 programı kullanıldı.Bulgular: Çalışmaya 30 hasta dahil edildi. Hastaların tamamı erkek idi ve yaş ortalaması 57,9±13,3 idi.Evre dağılı-mına bakıldığında, 12 hasta sınırlı evrede iken 18 hasta yaygın evrede idi. Hastaların performans durumu genel ola-rak iyi olup, ECOGa göre %43ü 1, %30u 0 idi ve evreye göre performans durumu analiz edildiğinde sınırlı evre ileyaygın evre arasında anlamlı fark saptandı (p=0.027). Yaş ortalaması SH evresi ile YH evresi arasında anlamlı farkvardı ( p=0.01). En sık metastaz yeri karaciğer (KC, %39), kemik (%25) ve beyin (%14)dir. Sınırlı evrede 2 hasta-da, YH evresinde 4 hastada paraneoplastik sendrom gözlenirken, en sık uygunsuz ADH sendromu saptandı. Ortancatrombosit sayısı 288±116/mm³ iken, SH evresinde 319±70/mm³ ve YH evresinde 268±136/mm³ olup aradaki fark is -tatistiksel olarak anlamlı değildi (p=0.24). YH evresinde 5 hastada (%17), SH evresinde hiç bir hastada trombosito-peni tespit edilmiştir. Bu sonuç istatistiki olarak anlamlıdır (p=0.047).Sonuç: Trombosit sayısı yaygın hastalık evresinde anlamlı olarak azalmış bulundu. Evreye göre diğer hematolojikparametreler arasında anlamlı fark saptanmadı. Daha büyük hasta gruplarında hematolojik parametrelerin değerlendirmesi uygun olacaktır.

A cross-sectional study on small cell lung cancer patients; The frequency of thrombocytopenia

Aim: We aimed to evaluate the demographic features and the frequency of thrombocytopenia for the patients withSCLC.Material and method: We retrospectively evaluated the datas of the patients with SCLC who admitted to our clinicbetween January 2008- May 2011. Besides demographical features, pretreatment platelet levels were recorded. Forstatistics, SPSS version14 was used. Results: Totally fles of 30 patients were evaluated. All were male and mean age was 57,9±13,3 years. 12 patientswere limited and 18 were extended stage. The difference between stages was signifcant as for age (p:0,01). ECOGperformance status was 0 in %30 and 1 in %43 of patients and there was a signifcant difference in between limitedand extended stages for performance status of patients (p: 0,027). Most common metastatic sites were liver (%39),bones (%25) and brain (%14). Syndrome of inappropriate ADH secretion was the most common paraneoplastic syn- drome and was observed in 6 patients (2 of them were limited stage).Median platelet count was 288±116/mm³ in the whole group; 317±70/mm³ in limited stage and 268±136/mm³ inextended stage. The difference in between stages was not signifcant (p:0,24).While thrombocytopenia was detected in 5 patients (%17) in the extended stage of the disease, no thrombocytopeniawas detected in any patients in the limited stage of the disease. The result is signifcant as for the extended stage(p=0.047). Conclusion: The platelet count was found to be signifcantly decreased in the extended stage of the disease. Therewas no signifcant difference between the other hematological parameters based on the stage. Evaluation of the he- matological parameters in larger patient groups would be appropriate.

PDF

___

1. Sher T, Grace K, Adjei AA. Small cell lung cancer. In: Tefferi A, Raj- kumar SV, Kantarjian HM, Adjei AA (eds). Neoplastic hematology and medical oncology. Mayo Klinic Rochester, Mayo Foundation for medical education and research; 2008. p. 267-279.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108.
3. Govindan R, Page N, Morgensztern D, et al. Changing epidemio - logy of small-cell lung cancer in the United States over the last 30 ye - ars: analysis of the surveillance, epidemiologic, and end results databa- se. J Clin Oncol. 2006; 24:4539-4544.
4. Ukena D, Huwer H, Dornhoff W. Bronchialkarzinome. In: Preiss , Dornhoff , Hagmann , Schmieder (eds). Onkologie 2008/09. 14. ed. München, W. Zuckschwerdt Verlag; 2008. p. 86-89.
5. Niederle N, Weidmann B, Budach V, et al. Kleinzelliges Bronchial- karzinom. In: Schmoll HJ, Höffken K, Possinger K(eds)(. Kompendi- um Internistische Onkologie. Berlin, Springer; 1997. p. 521-557.
6. Murren JR, Turrisi AT, Pass HI. Small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer. 7th edition. Philadelphia, Lippincott Williams & Wilkins; 2005. p. 810-843.
7. Wolf M. Kleinzellige Bronchialkarzinome. Onkologe.1998; 4:1005- 1018.
8. Edelman MJ, Gandara DR. Lung cancer. In: Casciato DA, Territo MC (eds). Manual of clinical oncology. Philadelphia, W Kluwer / Lip- pincott Williams & Wilkins; 2009. p. 169-187.
9. Dearing MP, Steinberg SM, Anderson M,et al. Outcome of patients with small cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. L Clin Oncol. 1990; 8: 1042-1094.
10. Ruckdeschel JC, Schwartz AG, Bepler G,et al. Cancer of the lung: NSCLC and SCLC. In: Abeloff MD, Armitage JO, Niederhuber JE,et al (eds). Clinical oncology. Phialdelphia, Elsevier; 2004. p. 1649-1743.
11. MohanA, Goyal A, Singh P, Singh S, Pathak AK*, Bhutani M*, Pandey RM**, Guleria R .Survival in small cell lung cancer in India:Prognostic utility of clinical features,laboratory parameters and response totreatment. Indian Journal of Cancer | AprilJune 2006 | Vo - lume 43 | Issue 2.
12. Chee-Keong Toh, Siew-Wan Hee at all.Survival of Small-cell Lung Cancer and its Determinants of Outcome in Singapore. Ann Acad Med Singapore. 2007;36:181-188.
13. Ross PJ, Ashley S, Norton A et al. (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer .2004; 90 (10): 19051911.
14. Osterlind K, Ihde DC, Ettinger DS, Gralla RJ, Karrer K, Krauss S, et al. Staging and prognostic factors in small cell carcinoma of the lung. Cancer Treat Rep. 1983; 67:3-9.
15. Maestu I, Pastor M, Gomez-Codina J, Aparicio J, Oltra A, Herranz C, et al. Pretreatment prognostic factors for survival in small cell lung cancer: A new prognostic index and validation of three new prognostic indices on 341 patients. Ann Oncol. 1997; 8:547-553.
16. Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prog - nostic factors in 766 patients with small cell lung cancer: The role of sex as a predictor of survival. Br J Cancer. 1991; 63:986-992.
17. Tsao AS, Liu D, Lee JJ et al. Smoking Affects Treatment Outcome in Patients with Advanced Nonsmall Cell lung Cancer. Cancer. 2006; 106 (11): 24282436.
18. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronc - hial epithelium of current and former smokers. J NatlCancer Inst. 1997; 89: 13661373.